vs

Side-by-side financial comparison of Phathom Pharmaceuticals, Inc. (PHAT) and Plymouth Industrial REIT, Inc. (PLYM). Click either name above to swap in a different company.

Phathom Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($57.6M vs $51.2M, roughly 1.1× Plymouth Industrial REIT, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs -1.4%).

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.

Plymouth Industrial REIT, Inc. is a real estate investment trust focused on owning, operating, and acquiring high-quality industrial properties including distribution centers, warehouses, and light industrial facilities across key U.S. logistics hubs. It serves tenants in e-commerce, retail, manufacturing, and third-party logistics sectors, supporting diverse business supply chain needs.

PHAT vs PLYM — Head-to-Head

Bigger by revenue
PHAT
PHAT
1.1× larger
PHAT
$57.6M
$51.2M
PLYM
Growing faster (revenue YoY)
PHAT
PHAT
+95.5% gap
PHAT
94.1%
-1.4%
PLYM

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
PHAT
PHAT
PLYM
PLYM
Revenue
$57.6M
$51.2M
Net Profit
$-54.4M
Gross Margin
86.7%
Operating Margin
-102.5%
Net Margin
-106.3%
Revenue YoY
94.1%
-1.4%
Net Profit YoY
71.6%
-248.5%
EPS (diluted)
$-1.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PHAT
PHAT
PLYM
PLYM
Q4 25
$57.6M
Q3 25
$49.5M
$51.2M
Q2 25
$39.5M
$47.2M
Q1 25
$28.5M
$45.6M
Q4 24
$29.7M
$47.6M
Q3 24
$16.4M
$51.9M
Q2 24
$7.3M
$48.7M
Q1 24
$50.2M
Net Profit
PHAT
PHAT
PLYM
PLYM
Q4 25
Q3 25
$-30.0M
$-54.4M
Q2 25
$-75.8M
$-6.1M
Q1 25
$-94.3M
$5.8M
Q4 24
$147.4M
Q3 24
$-85.6M
$-15.6M
Q2 24
$-91.4M
$1.3M
Q1 24
$6.2M
Gross Margin
PHAT
PHAT
PLYM
PLYM
Q4 25
86.7%
Q3 25
87.5%
Q2 25
87.2%
Q1 25
86.9%
Q4 24
87.1%
Q3 24
85.6%
Q2 24
81.2%
Q1 24
Operating Margin
PHAT
PHAT
PLYM
PLYM
Q4 25
Q3 25
-30.8%
-102.5%
Q2 25
-151.7%
-10.3%
Q1 25
-276.5%
Q4 24
Q3 24
-433.0%
-29.6%
Q2 24
-1055.4%
2.7%
Q1 24
Net Margin
PHAT
PHAT
PLYM
PLYM
Q4 25
Q3 25
-60.5%
-106.3%
Q2 25
-191.9%
-12.9%
Q1 25
-330.7%
12.8%
Q4 24
309.9%
Q3 24
-523.3%
-30.1%
Q2 24
-1248.6%
2.7%
Q1 24
12.4%
EPS (diluted)
PHAT
PHAT
PLYM
PLYM
Q4 25
Q3 25
$-0.41
$-1.23
Q2 25
$-1.05
$-0.14
Q1 25
$-1.31
$0.13
Q4 24
$3.24
Q3 24
$-1.32
$-0.35
Q2 24
$-1.56
$0.03
Q1 24
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PHAT
PHAT
PLYM
PLYM
Cash + ST InvestmentsLiquidity on hand
$130.0M
Total DebtLower is stronger
$209.1M
Stockholders' EquityBook value
$-438.2M
$470.1M
Total Assets
$259.1M
$1.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PHAT
PHAT
PLYM
PLYM
Q4 25
$130.0M
Q3 25
$135.2M
Q2 25
$149.6M
Q1 25
$212.3M
Q4 24
$297.3M
Q3 24
$334.7M
Q2 24
$276.2M
Q1 24
Total Debt
PHAT
PHAT
PLYM
PLYM
Q4 25
$209.1M
Q3 25
$207.1M
Q2 25
$205.1M
Q1 25
$203.2M
Q4 24
$201.4M
$646.4M
Q3 24
$175.7M
Q2 24
$174.4M
Q1 24
Stockholders' Equity
PHAT
PHAT
PLYM
PLYM
Q4 25
$-438.2M
Q3 25
$-422.5M
$470.1M
Q2 25
$-405.8M
$539.6M
Q1 25
$-338.4M
$571.0M
Q4 24
$-253.6M
$579.5M
Q3 24
$-187.1M
$436.5M
Q2 24
$-233.8M
$475.2M
Q1 24
$484.6M
Total Assets
PHAT
PHAT
PLYM
PLYM
Q4 25
$259.1M
Q3 25
$240.3M
$1.6B
Q2 25
$250.2M
$1.6B
Q1 25
$294.2M
$1.4B
Q4 24
$378.3M
$1.4B
Q3 24
$387.0M
$1.5B
Q2 24
$319.4M
$1.4B
Q1 24
$1.4B
Debt / Equity
PHAT
PHAT
PLYM
PLYM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
1.12×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PHAT
PHAT
PLYM
PLYM
Operating Cash FlowLast quarter
$-166.8M
$20.0M
Free Cash FlowOCF − Capex
$-167.0M
FCF MarginFCF / Revenue
-290.0%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-328.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PHAT
PHAT
PLYM
PLYM
Q4 25
$-166.8M
Q3 25
$-14.1M
$20.0M
Q2 25
$-62.7M
$23.4M
Q1 25
$-84.9M
$15.6M
Q4 24
$-266.8M
$96.1M
Q3 24
$-63.6M
$17.6M
Q2 24
$-70.7M
$19.9M
Q1 24
$16.6M
Free Cash Flow
PHAT
PHAT
PLYM
PLYM
Q4 25
$-167.0M
Q3 25
$-14.1M
Q2 25
$-62.8M
Q1 25
$-84.9M
Q4 24
$-266.9M
Q3 24
$-63.6M
Q2 24
$-70.8M
Q1 24
FCF Margin
PHAT
PHAT
PLYM
PLYM
Q4 25
-290.0%
Q3 25
-28.6%
Q2 25
-159.0%
Q1 25
-297.9%
Q4 24
-899.8%
Q3 24
-389.0%
Q2 24
-966.2%
Q1 24
Capex Intensity
PHAT
PHAT
PLYM
PLYM
Q4 25
0.4%
Q3 25
0.1%
Q2 25
0.2%
Q1 25
0.1%
Q4 24
0.5%
Q3 24
0.3%
Q2 24
0.6%
Q1 24
Cash Conversion
PHAT
PHAT
PLYM
PLYM
Q4 25
Q3 25
Q2 25
Q1 25
2.67×
Q4 24
0.65×
Q3 24
Q2 24
15.12×
Q1 24
2.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons